Anthranilamide Derivatives Research Articles

Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors

Paclitaxel (PTX) is considered the blockbuster chemotherapy treatment for cancer. Paclitaxel's (PTX) oral administration has proven to be extremely difficult, mostly because of its susceptibility to intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP3A4). The concurrent local inhibition of intestinal P-gp and CYP3A4 is a promising approach to improve the oral bioavailability of paclitaxel while avoiding potential unfavorable side effects of their systemic inhibition. Herein, we report the rational design and evaluation of novel dual potent inhibitors of P-gp and CYP3A4 using an anthranilamide derivative tariquidar as a starting point for their structural optimizations. Compound 14f, bearing N-imidazolylbenzyl side chain, was found to have potent and selective P-gp (EC50 = 28 nM) and CYP3A4 (IC50 = 223 nM) inhibitory activities with low absorption potential (Papp (A-to-B) <0.06). In vivo, inhibitor 14f improved the oral absorption of paclitaxel by 6 times in mice and by 30 times in rats as compared to vehicle, while 14f itself remained poorly absorbed. Compound 14f, possessing dual P-gp and CYP3A4 inhibitory activities, offered additional enhancement in paclitaxel oral absorption compared to tariquidar in mice. Evaluating the CYP effect of 14f on oral absorption of paclitaxel requires considering the variations in CYP expression between animal species. This study provides further medicinal chemistry advice on strategies for resolving concerns with the oral administration of chemotherapeutic agents.

Ruthenium-Catalyzed Aminocarbonylation with Isocyanates Through Weak Coordinating Groups.

Introducing amide functional groups under mild conditions has growing importance owing to the prevalence of such moiety in biologically active molecules. Herein, we disclose a mild protocol for the directed ruthenium-catalyzed C-H aminocarbonylation with isocyanates as the amidating agents developed through high-throughput experimentation (HTE). The redox-neutral and base-free reaction is guided by weakly Lewis basic functional groups, including anilides, lactams and carbamates to access anthranilamide derivatives. The synthetic utility of this transformation is reflected by large-scale synthesis and late-stage functionalization.

Brevicalamide, a new anthranilamide from Aconitum brevicalcaratum, suggests a new type of chemotaxonomic marker for tribe Delphineae

Tribe Delphineae (Ranunculaceae), composed of two closely related genera, i.e., Aconitum L. and Delphinium L., is fame for its taxonomic complexity. Using chemotaxonomy to assist and supplement its taxonomy is of significance. In the present study, three anthranilamide derivatives (1–3), including a new compound, brevicalamide (1), were isolated from the China-specific Delphineae plant Aconitum brevicalcaratum Diels. The chemotaxonomic significance of the isolated compounds along with other analogs was discussed for the first time. Anthranilamide derivatives exhibited certain chemotaxonomic potential and could serve as a new type of chemical marker to provide useful information for the chemotaxonomy of this phytogroup.

Indole and azaindole halogenation catalyzed by the RebH enzyme variant 3-LSR utilizing co-purified E. coli reductase.

Biocatalytic C-H halogenation is becoming increasingly attractive due to excellent catalyst-controlled selectivity and environmentally benign reaction conditions. Significant efforts have been made on enzymatic halogenation of industrial arenes in a cost-effective manner. Here we report an unprecedented enzymatic halogenation of a panel of industrially important indole, azaindole and anthranilamide derivatives using a thermostable RebH variant without addition of any external flavin reductase enzyme. The reactions were catalyzed by the RebH variant 3-LSR enzyme with the help of a co-purified E. coli reductase identified as alkyl hydroperoxide reductase F (AhpF).

Synthesis and characterization of 2-Benzamido-NBenzylbenzamide Derivative

Anthranilamide derivatives exhibit anti-inflammatory, antipyretic, antibacterial, antiangiogenic, and anticoagulant properties. With an early in silico examination of its analgesic capabilities, this study aimed to generate a novel anthranilamide molecule by altering 2-Benzamido-N-Benzylbenzamide. Modification of anthranilamide with 1/2/3-chloro benzoyl chloride by acylation resulted in the design, synthesis, characterization, and research of the analgesic effects of 2-benzamido-N-benzoylbenzamide derivatives. 2-(2-chlorobenzamido)-N-(2-chlorobenzoyl)benzamide, 2-(3-chlorobenzamido)-N-(3-chlorobenzoyl)benzamide, and 2-(4-chlorobenzamido)-N-(4-chlorobenzoyl)benzamide were prepared. The nucleophilic acyl substitution reaction method was used to prepare these three chemicals by interaction with anthranylamide and benzoyl chloride molecules. Melting point and thin-layer chromatography were used to check the purity of the synthesis fi ndings. The structure was confi rmed by UV-Vis and infrared spectrophotometry.

Design, synthesis and biological evaluation of Piperazinylanthranilamides as potential factor Xa inhibitors

Direct inhibition of FXa has emerged as an effective strategy to achieve anticoagulation maintaining normal hemostasis with minimal bleeding risks. A novel series of anthranilamide derivatives have been designed and synthesized wherein the bonding order of carbonyl and amino groups of both P1 and P4 motifs in the anthranilamide core structure has been reversed. In order to improve the selectivity for FXa, haloaromatic groups present in the reported FXa inhibitors were retained, while substituted phenylpiperazinylamides were used as S4 binding ligands to improve the physicochemical properties of the resulting compounds. Compounds (6y and 7f) exhibited the most potent FXa inhibitory activities with IC50 values of 0.6 µM and 0.74 µM exhibiting high selectivity over thrombin. Both compounds displayed good anticoagulant activity in rats. Compound (6y) displayed a safety profile similar to the standard drug rivaroxaban in bleeding risk assessment. Simulation studies like molecular docking and molecular dynamics supported strong binding of the analogs to the enzyme FXa

Fluorescent Biaryl Uracils with C5-Dihydro- and Quinazolinone Heterocyclic Appendages in PNA.

There has been much effort to exploit fluorescence techniques in the detection of nucleic acids. Canonical nucleic acids are essentially nonfluorescent; however, the modification of the nucleobase has proved to be a fruitful way to engender fluorescence. Much of the chemistry used to prepare modified nucleobases relies on expensive transition metal catalysts. In this work, we describe the synthesis of biaryl quinazolinone-uracil nucleobase analogs prepared by the condensation of anthranilamide derivatives and 5-formyluracil using inexpensive copper salts. A selection of modified nucleobases were prepared, and the effect of methoxy- or nitro- group substitution on the photophysical properties was examined. Both the dihydroquinazolinone and quinazolinone modified uracils have much larger molar absorptivity (~4–8×) than natural uracil and produce modest blue fluorescence. The quinazolinone-modified uracils display higher quantum yields than the corresponding dihydroquinazolinones and also show temperature and viscosity dependent emission consistent with molecular rotor behavior. Peptide nucleic acid (PNA) monomers possessing quinazolinone modified uracils were prepared and incorporated into oligomers. In the sequence context examined, the nitro-substituted, methoxy-substituted and unmodified quinazolinone inserts resulted in a stabilization (∆Tm = +4.0/insert; +2.0/insert; +1.0/insert, respectively) relative to control PNA sequence upon hybridization to complementary DNA. All three derivatives responded to hybridization by the “turn-on” of fluorescence intensity by ca. 3-to-4 fold and may find use as probes for complementary DNA sequences.

Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors

A series of anthranilamide derivatives were designed and synthesized as novel smoothened (SMO) inhibitors based on the SMO inhibitor taladegib (LY2940680), which can also inhibit the SMO-D473H mutant, via a ring-opening strategy. The phthalazine core in LY2940680 was replaced with anthranilamide, which retained the inhibitory activity towards the hedgehog (Hh) signaling pathway as evidenced by a dual luciferase reporter gene assay. Compound 12a displayed the best inhibitory activity against the Hh signaling pathway with IC50 value of 34.09 nM, and exhibited better proliferation inhibitory activity towards the Daoy cell line (IC50 = 0.48 μM) than LY2940680 (IC50 = 0.79 μM).

A new prenylated coumarin and a new anthranilamide derivative from Evodia lepta

A new prenylated coumarin (1) and a new anthranilamide derivative (2) were isolated from the aerial parts of Evodia lepta. Compound 2 represents the first anthranilamide derivative from the Evodia genus. Their structures were elucidated by spectroscopic data analysis (MS, UV, IR, and NMR). Compound 1 exhibited certain inhibition on nitric oxide (NO) production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages with an IC50 value of 37.96 ± 1.7 μM.

Synthesis, molecular packing and anti-cholinesterase activity of some new C-2 N-substituted anthranilamide derivatives

Abstract Synthesis of C-2 N-substituted anthranilamide derivatives was carried out in a straight forward manner, utilizing 2-aminobenzamide and benzyl chloride as starting materials. Their crystal structures have been established by single crystal X-ray crystallographic method. In the molecules of 2-benzylamino-benzamide (3a), intramolecular hydrogen bonding b/w O atom and proton of –NH and classical intermolecular hydrogen bonding of the type N–H · · · O forming eight membered rings in R4 2(8) pattern. In both molecules of 2-(dibenzylamino)benzamide (3b), unlike the molecule in 3a, each H atoms is pointed towards N atom causing intramolecular hydrogen bonding interactions, resulting in S(6) motifs. However, it is interesting to note that both molecules in 3b are lying about inversion centres and form dimers in R4 2(8) motifs; the two dimers are linked via non-classical intermolecular hydrogen bonds C–H · · · O resulting in clusters of four molecules in the structure. In vitro assay results revealed that molecule 3b with IC50 values of 3.8 ± 0.08 μM (AChE) and 17.6 ± 1.10 μM (BChE) possessed better cholinesterase (AChE and BChE) inhibition potential as compared to standard drug galantamine. Preliminary in silico studies showed that more biological active derivatives were also having good pharmacokinetic profile with no AMES toxicity and carcinogenicity.

Synthesis of New Quinazolin‐4‐(3H)‐one Derivatives and Evaluation of Their Biological Activities

AbstractA new series of quinazolin‐4‐ones are conveniently synthesized in a one‐pot procedure from anthranilamide derivatives and aldehydes using p‐toluenesulfonic acid as a catalyst. The aim of inserting azo pyridyl and 4‐amino benzamide groups in the structure of quinazolin‐4‐one derivatives is to achieve skeletal appearance with more antibacterial and antifungal properties. Therefore, the biological activities of the synthetic compounds were studied. The results revealed that almost all compounds exhibit antimicrobial activities.

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.

Seven new anthranilamide derivatives from Aconitum apetalum

Seven new anthranilamide derivatives, acoapetalines A-G (1–7), including one new naturally occurring compound (7), together with six known ones (8–13) were isolated from the whole plants of Aconitum apetalum. Their structures were established on the basis of extensive spectroscopic analyses (IR, UV, HRESIMS, 1D and 2D NMR). All compounds were evaluated for their anti-tobacco mosaic virus (anti-TMV) activities. The results showed that compound 10 exhibited significant anti-TMV activity with an inhibition rate of 67.57% (100 μg/mL), which was higher than that of ningnamycin (52.89%).

ChemInform Abstract: Bridgehead Bicyclo[4.4.0]boron Heterocycles: A One‐Pot Four‐Component Synthesis of Dibenzo[e,i][1,3,7,2]oxadiazaborecin‐8(7H)‐ones.

A one-pot four-component synthesis of 6-aryl-6H-dibenzo[e,i][1,3,7,2]oxadiazaborecin-8(7H)-ones is described. Heating a mixture of isatoic anhydride and a benzylamine afforded the corresponding anthranilamide derivative, which was condensed with a 2-hydroxybenzaldehyde and an arylboronic acid under solvent-free conditions to produce bridgehead bicyclo[4.4.0]-boron heterocycles in good to excellent yields. Single-crystal X-ray analysis conclusively confirms the structures of the obtained bridgehead bicyclic 6–6 heterocyclic compounds.

Bridgehead Bicyclo[4.4.0]boron Heterocycles: A One‐Pot Four‐Component Synthesis of Dibenzo[e,i][1,3,7,2]oxadiazaborecin‐8(7H)‐ones

A one‐pot four‐component synthesis of 6‐aryl‐6H‐dibenzo[e,i][1,3,7,2]oxadiazaborecin‐8(7H)‐ones is described. Heating a mixture of isatoic anhydride and a benzylamine afforded the corresponding anthranilamide derivative, which was condensed with a 2‐hydroxybenzaldehyde and an arylboronic acid under solvent‐free conditions to produce bridgehead bicyclo[4.4.0]‐boron heterocycles in good to excellent yields. Single‐crystal X‐ray analysis conclusively confirms the structures of the obtained bridgehead bicyclic 6–6 heterocyclic compounds.

Identification of anthranilamide derivatives as potential factor Xa inhibitors: Drug design, synthesis and biological evaluation

The coagulation enzyme factor Xa (fXa) plays a crucial role in the blood coagulation cascade. In this study, three-dimensional fragment based drug design (FBDD) combined with structure-based pharmacophore (SBP) model and structural consensus docking were employed to identify novel fXa inhibitors. After a multi-stage virtual screening (VS) workflow, two hit compounds 3780 and 319 having persistent high performance were identified. Then, these two hit compounds and several analogs were synthesized and screened for in-vitro inhibition of fXa. The experimental data showed that most of the designed compounds displayed significant in vitro potency against fXa. Among them, compound 9b displayed the greatest in vitro potency against fXa with the IC50 value of 23 nM and excellent selectivity versus thrombin (IC50 = 40 μM). Moreover, the prolongation of the prothrombin time (PT) was measured for compound 9b to evaluate its in vitro anticoagulant activity. As a result, compound 9b exhibited pronounced anticoagulant activity with the 2 × PT value of 8.7 μM.

Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system

Anticoagulant agents have emerged as a promising class of therapeutic drugs for the treatment and prevention of arterial and venous thrombosis. We investigated a series of novel orally active factor Xa inhibitors designed using our previously reported conjugation strategy to boost oral anticoagulant effect. Structural optimization of anthranilamide derivative 3 as a lead compound with installation of phenolic hydroxyl group and extensive exploration of the P1 binding element led to the identification of 5-chloro-N-(5-chloro-2-pyridyl)-3-hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzamide (33, AS1468240) as a potent factor Xa inhibitor with significant oral anticoagulant activity. We also reported a newly developed Free-Wilson-like fragment recommender system based on the integration of R-group decomposition with collaborative filtering for the structural optimization process.

Beyond Directed Ortho Metalation: Ruthenium-Catalyzed Amide-Directed CAr–N Activation/C–C Coupling Reaction of Anthranilamides with Organoboronates

A new, catalytic, and general methodology for the synthesis of biaryls and heterobiaryls by the cross coupling of anthranilamide derivatives (o-NMe2 benzamides) with aryl boroneopentylates is described. The reaction proceeds under catalytic RuH2(CO)(PPh3)3 conditions driven by the activation of the unreactive C-N bond by amide directing group (DG)-Ru catalyst chelation. High regioselectivity, orthogonality with the Suzuki-Miyaura reaction, operational simplicity, and convenient scale-up are features of these reactions which may lend themselves to industrial applications.

2-Cinnamamido, 2-(3-phenylpropiolamido), and 2-(3-phenylpropanamido)benzamides: Synthesis, antiproliferative activity, and mechanism of action

Several new benzamides 4a–q were synthesized by stirring in pyridine the acid chlorides 3a–q with the appropriate anthranilamide derivatives 2a–g. Some of the synthesized compounds were evaluated for their in vitro antiproliferative activity against a panel of 5 human cell lines (K562 human chronic myelogenous leukemia cells, MCF-7 breast cancer cells, HTC-116 and HT26 colon cancer cells and NCI H460 non-small cell lung cancer cells).

Synthesis and biological evaluation of novel anthranilamide derivatives as anticancer agents

A new series of anthranilamide derivatives were synthesized and evaluated for their antiproliferative activities against human colon carcinoma cell lines (HCT 116) and human breast adenocarcinoma cell lines (MDA-MB-231) in vitro. The bioassay results indicated that compounds 7a-7d, 11a, and 11b with flexible linkers showed promising antiproliferative activity against both cell lines. Among the compounds synthesized, 7c showed the most significant antiproliferative activity. Flow cytometric analysis indicated that 7c inhibited HCT 116 and MDA-MB-231 cell growth by inducing apoptosis in a dose-dependent manner and suppressed HCT 116 cell proliferation by G1 and S phase arrest. Compound 7c may serve as a lead candidate in the development of novel anticancer agents.